NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
NR 566 / NR566 Final Exam Qs & Ans (Latest )
Advanced Pharmacology for Care of the Family — Verified Answers
185 Questions • 10 Sections • Cognitive Levels: 30% Recall / 50% Application / 20% Analysis
75% Scenario-Based • 25% Direct Recall • Comprehensive Rationales as Study Content
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan (Absorption,
Distribution, Metabolism, Excretion, & Age-Related Considerations)
Q1: A 78-year-old female with heart failure is prescribed furosemide 40 mg PO twice daily. Compared to a
30-year-old, which age-related pharmacokinetic change most increases this patient's risk of toxicity?
A. Increased glomerular filtration rate enhances drug clearance
B. Reduced hepatic blood flow prolongs the half-life of highly extracted drugs
C. Decreased total body water and lean body mass raise drug plasma concentrations [CORRECT]
D. Enhanced gastric acid production accelerates absorption of weak bases
Correct Answer: C
Rationale: Aging reduces total body water and lean muscle mass, lowering the volume of distribution (Vd) for
water-soluble drugs like furosemide, which raises peak plasma concentrations. GFR declines with age (not increases),
reducing renal clearance of diuretics and active metabolites. Hepatic blood flow and CYP activity also decline, but the
most direct cause of heightened toxicity risk in this scenario is the contracted Vd for hydrophilic drugs. APRNs must
dose-adjust diuretics in older adults using estimated creatinine clearance, not serum creatinine alone, because
sarcopenia masks renal impairment.
Q2: A neonate (postnatal day 3) requires ampicillin for early-onset sepsis. Which pharmacokinetic feature of
the neonatal liver is most clinically relevant when determining dosing interval?
A. Fully mature glucuronidation pathways producing rapid clearance
B. Immature glucuronyl transferase activity slowing Phase II metabolism [CORRECT]
C. Adult-level CYP3A4 activity generating metabolites faster than adults
D. Enhanced biliary excretion compensating for renal immaturity
Correct Answer: B
Rationale: Neonates, especially in the first weeks of life, have immature hepatic glucuronyl transferase (UGT)
activity, the Phase II enzyme responsible for glucuronidation of drugs such as chloramphenicol, morphine, and
zidovudine. This immaturity prolongs half-life and necessitates extended dosing intervals to avoid accumulation.
CYP3A4 activity is also reduced at birth (reaching adult levels around 1-3 months), while renal immaturity cannot be
compensated by biliary excretion. The APRN must consult neonatal weight-based dosing references and consider
postnatal age in days, not just weight, when calculating intervals.
Q3: A patient with severe Crohn's disease and a 12-inch terminal ileum resection is started on an oral
medication with primarily ileal absorption. Which pharmacokinetic parameter is most affected by this
surgery?
A. Volume of distribution (Vd)
B. Metabolism (Phase I oxidation)
Page 1 | Verified Answers & Rationales
,NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
C. Bioavailability (F) [CORRECT]
D. Renal clearance (CLr)
Correct Answer: C
Rationale: Terminal ileum resection removes the primary absorption site for vitamin B12, bile acids, and many orally
administered drugs that depend on ileal transporters. Bioavailability (F), the fraction of administered dose reaching
systemic circulation, is the parameter most directly reduced because absorption is the rate-limiting step. Vd,
metabolism, and renal clearance are largely independent of ileal integrity for systemically absorbed drugs. APRNs
should consider alternative routes (IV, sublingual, transdermal) or compound formulations for patients with extensive
small bowel resection to ensure therapeutic drug levels.
Q4: A 6-month-old infant is prescribed phenobarbital for seizures. The APRN knows infants have a higher
per-kilogram dose requirement than adults for many anticonvulsants. What pharmacokinetic rationale best
explains this?
A. Increased plasma protein binding reducing free drug fraction
B. Larger liver-to-body-mass ratio and enhanced metabolic clearance per kg [CORRECT]
C. Decreased extracellular fluid volume concentrating the drug
D. Reduced blood-brain barrier permeability requiring higher doses
Correct Answer: B
Rationale: Infants (especially 2-6 months) have a proportionally larger liver relative to body weight, and CYP enzyme
activity per kilogram often exceeds adult values during this developmental window, accelerating clearance of drugs
like phenobarbital, phenytoin, and levetiracetam. Plasma protein binding is actually reduced in infants (lower albumin
and alpha-1-acid glycoprotein), increasing free fraction. Extracellular fluid volume is increased, not decreased, diluting
the dose. APRNs must use weight-based pediatric dosing and monitor serum levels when available because infant
kinetics do not linearly scale from adult doses.
Q5: Which statement correctly characterizes a drug with a narrow therapeutic index (NTI) such as warfarin?
A. Toxic dose is dramatically higher than therapeutic dose, allowing wide dosing latitude
B. Small changes in dose or plasma concentration can produce serious toxicity or therapeutic failure
[CORRECT]
C. Monitoring plasma levels is unnecessary because efficacy reliably tracks dose
D. Genetic polymorphisms do not meaningfully affect dosing requirements
Correct Answer: B
Rationale: Narrow therapeutic index (NTI) drugs like warfarin, digoxin, lithium, phenytoin, and theophylline have
toxic concentrations very close to therapeutic concentrations, so modest dose or concentration changes can precipitate
harm or loss of efficacy. Therapeutic drug monitoring (TDM) is mandatory, and individualization is essential,
including pharmacogenomic considerations such as CYP2C9 and VKORC1 for warfarin. APRNs must counsel
patients on consistency (diet, adherence, interacting drugs) and monitor INR, serum levels, or other validated markers
rather than relying on dose alone.
Q6: A patient taking warfarin 5 mg daily for atrial fibrillation is newly started on amiodarone for rhythm
control. Within 3 weeks, the INR rises to 8.4 with no bleeding. Which pharmacokinetic mechanism best
explains this interaction?
A. Amiodarone induces CYP2C9, increasing warfarin activation
B. Amiodarone and its metabolite desethylamiodarone inhibit CYP2C9, reducing warfarin clearance
[CORRECT]
Page 2 | Verified Answers & Rationales
,NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
C. Amiodarone displaces warfarin from albumin only, with no clinical impact
D. Amiodarone enhances renal warfarin excretion
Correct Answer: B
Rationale: Amiodarone is a potent CYP2C9 inhibitor; both the parent drug and its active metabolite
desethylamiodarone reduce S-warfarin clearance, dramatically potentiating anticoagulation and requiring a 25-50%
empiric warfarin dose reduction. Although amiodarone also displaces warfarin from protein binding, this effect is
transient and clinically minor compared with the metabolic inhibition. CYP2C9 inhibition is the dominant mechanism.
APRNs should anticipate the interaction, check INR within 7-14 days, and adjust the warfarin dose proactively rather
than reactively.
Q7: A 72-year-old male with CKD stage 4 (eGFR 22 mL/min/1.73 m²) requires treatment for a confirmed
Pseudomonas urinary tract infection. The APRN selects gentamicin. Which pharmacokinetic principle guides
dosing?
A. Loading and maintenance doses both remain at standard adult values
B. Use standard loading dose but extend the dosing interval based on renal function [CORRECT]
C. Reduce loading dose and shorten the dosing interval
D. Switch to oral therapy because the patient has UTI only
Correct Answer: B
Rationale: For renally cleared drugs with a narrow therapeutic index such as aminoglycosides, the loading dose
(dependent on Vd) typically remains unchanged in renal impairment because Vd is not significantly altered, but the
maintenance interval must be extended (extended-interval dosing) or the maintenance dose reduced to prevent
accumulation. Oral gentamicin is not absorbed systemically and cannot treat systemic Pseudomonas. APRNs should
use a renal dosing calculator or the Cockcroft-Gault equation, monitor peak/trough levels (or area-under-curve targets),
and counsel patients on ototoxicity and nephrotoxicity warning signs.
Q8: Which drug exhibits the longest elimination half-life among the following, requiring weeks to reach
steady state?
A. Furosemide
B. Amiodarone [CORRECT]
C. Metformin
D. Lisinopril
Correct Answer: B
Rationale: Amiodarone has an exceptionally long half-life of approximately 25-60 days (and up to 100 days in some
individuals) due to extensive tissue distribution and slow lysosomal sequestration, meaning steady state may take 3-6
months to achieve. Furosemide (~2 hours), metformin (~6 hours), and lisinopril (~12 hours) all reach steady state
within 1-2 days. APRNs must load amiodarone inpatient or outpatient for 1-3 weeks (10 g total load) before
maintenance, and recognize that effects (and toxicity such as pulmonary fibrosis, hepatotoxicity, thyroid dysfunction)
persist for months after discontinuation.
Q9: A drug with high first-pass metabolism and low oral bioavailability is most likely administered by which
route for systemic effect?
A. Oral immediate-release tablet
B. Sublingual, transdermal, or intravenous [CORRECT]
C. Rectal suppository
Page 3 | Verified Answers & Rationales
, NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
D. Intramuscular depot only
Correct Answer: B
Rationale: Drugs undergoing extensive hepatic first-pass metabolism (e.g., nitroglycerin, propranolol, morphine,
verapamil, levodopa) have very low oral bioavailability (F). Alternative routes that bypass the portal
circulation-sublingual, transdermal, IV, or in some cases intranasal-are required for predictable systemic effect.
APRNs must recognize that switching routes changes more than convenience: the effective dose, onset, and duration
all change. For example, nitroglycerin sublingual (0.3-0.6 mg) is ~10x more bioavailable than oral, so doses are not
interchangeable.
Q10: A 45-year-old female with hypothyroidism is prescribed levothyroxine 100 mcg daily. She reports taking
it with her breakfast of high-fiber cereal and coffee with milk. Her TSH is 14 mIU/mL (target 0.5-4.0). What
pharmacokinetic mechanism explains her persistent hypothyroidism?
A. Levothyroxine undergoes extensive first-pass metabolism reducing bioavailability
B. Food, calcium in milk, and coffee reduce levothyroxine absorption [CORRECT]
C. Levothyroxine is metabolized faster when taken with food
D. TSH elevation indicates non-adherence rather than absorption issues
Correct Answer: B
Rationale: Levothyroxine absorption occurs in the proximal small intestine (jejunum) and is highly sensitive to
anything that chelates, binds, or accelerates transit. Calcium (milk, supplements), iron, fiber, soy, coffee, and proton
pump inhibitors all significantly reduce absorption. Levothyroxine has minimal first-pass metabolism; the issue is
absorption, not metabolism. APRNs must counsel patients to take levothyroxine on an empty stomach 30-60 minutes
before food or beverages other than water, or alternatively at bedtime 3-4 hours after the evening meal, and to space
interacting medications by at least 4 hours.
Q11: A drug that is a partial agonist at the beta-1 adrenergic receptor, such as carvedilol in a patient with
severe heart failure, demonstrates which pharmacodynamic property?
A. Maximal efficacy equal to a full agonist at all receptor occupancies
B. Acts as an antagonist in the presence of a full agonist and an agonist in the absence of endogenous
ligand [CORRECT]
C. Has zero intrinsic activity and only blocks the receptor
D. Cannot produce any therapeutic effect regardless of dose
Correct Answer: B
Rationale: Partial agonists (e.g., carvedilol, pindolol, buprenorphine, varenicline, beta blockers with intrinsic
sympathomimetic activity) have lower intrinsic activity than full agonists. In the presence of high endogenous agonist
(e.g., catecholamines in heart failure), they behave as antagonists by competing for the receptor while producing less
effect, reducing sympathetic overdrive. In the absence of endogenous agonist, they produce a modest agonist effect,
preventing complete receptor silence. APRNs must recognize this dual behavior to predict effects when combining
partial agonists with full agonists or antagonists.
Q12: A pregnant patient at 28 weeks' gestation requires phenytoin for new-onset epilepsy. Which
pharmacokinetic change of pregnancy most significantly affects phenytoin levels?
A. Increased plasma albumin raising total drug concentration
B. Increased volume of distribution, increased renal clearance, and reduced protein binding lowering
total drug levels [CORRECT]
C. Reduced hepatic CYP activity causing accumulation
Page 4 | Verified Answers & Rationales
NR 566 / NR566 Final Exam Qs & Ans (Latest )
Advanced Pharmacology for Care of the Family — Verified Answers
185 Questions • 10 Sections • Cognitive Levels: 30% Recall / 50% Application / 20% Analysis
75% Scenario-Based • 25% Direct Recall • Comprehensive Rationales as Study Content
Section 1: Pharmacokinetics and Pharmacodynamics Across the Lifespan (Absorption,
Distribution, Metabolism, Excretion, & Age-Related Considerations)
Q1: A 78-year-old female with heart failure is prescribed furosemide 40 mg PO twice daily. Compared to a
30-year-old, which age-related pharmacokinetic change most increases this patient's risk of toxicity?
A. Increased glomerular filtration rate enhances drug clearance
B. Reduced hepatic blood flow prolongs the half-life of highly extracted drugs
C. Decreased total body water and lean body mass raise drug plasma concentrations [CORRECT]
D. Enhanced gastric acid production accelerates absorption of weak bases
Correct Answer: C
Rationale: Aging reduces total body water and lean muscle mass, lowering the volume of distribution (Vd) for
water-soluble drugs like furosemide, which raises peak plasma concentrations. GFR declines with age (not increases),
reducing renal clearance of diuretics and active metabolites. Hepatic blood flow and CYP activity also decline, but the
most direct cause of heightened toxicity risk in this scenario is the contracted Vd for hydrophilic drugs. APRNs must
dose-adjust diuretics in older adults using estimated creatinine clearance, not serum creatinine alone, because
sarcopenia masks renal impairment.
Q2: A neonate (postnatal day 3) requires ampicillin for early-onset sepsis. Which pharmacokinetic feature of
the neonatal liver is most clinically relevant when determining dosing interval?
A. Fully mature glucuronidation pathways producing rapid clearance
B. Immature glucuronyl transferase activity slowing Phase II metabolism [CORRECT]
C. Adult-level CYP3A4 activity generating metabolites faster than adults
D. Enhanced biliary excretion compensating for renal immaturity
Correct Answer: B
Rationale: Neonates, especially in the first weeks of life, have immature hepatic glucuronyl transferase (UGT)
activity, the Phase II enzyme responsible for glucuronidation of drugs such as chloramphenicol, morphine, and
zidovudine. This immaturity prolongs half-life and necessitates extended dosing intervals to avoid accumulation.
CYP3A4 activity is also reduced at birth (reaching adult levels around 1-3 months), while renal immaturity cannot be
compensated by biliary excretion. The APRN must consult neonatal weight-based dosing references and consider
postnatal age in days, not just weight, when calculating intervals.
Q3: A patient with severe Crohn's disease and a 12-inch terminal ileum resection is started on an oral
medication with primarily ileal absorption. Which pharmacokinetic parameter is most affected by this
surgery?
A. Volume of distribution (Vd)
B. Metabolism (Phase I oxidation)
Page 1 | Verified Answers & Rationales
,NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
C. Bioavailability (F) [CORRECT]
D. Renal clearance (CLr)
Correct Answer: C
Rationale: Terminal ileum resection removes the primary absorption site for vitamin B12, bile acids, and many orally
administered drugs that depend on ileal transporters. Bioavailability (F), the fraction of administered dose reaching
systemic circulation, is the parameter most directly reduced because absorption is the rate-limiting step. Vd,
metabolism, and renal clearance are largely independent of ileal integrity for systemically absorbed drugs. APRNs
should consider alternative routes (IV, sublingual, transdermal) or compound formulations for patients with extensive
small bowel resection to ensure therapeutic drug levels.
Q4: A 6-month-old infant is prescribed phenobarbital for seizures. The APRN knows infants have a higher
per-kilogram dose requirement than adults for many anticonvulsants. What pharmacokinetic rationale best
explains this?
A. Increased plasma protein binding reducing free drug fraction
B. Larger liver-to-body-mass ratio and enhanced metabolic clearance per kg [CORRECT]
C. Decreased extracellular fluid volume concentrating the drug
D. Reduced blood-brain barrier permeability requiring higher doses
Correct Answer: B
Rationale: Infants (especially 2-6 months) have a proportionally larger liver relative to body weight, and CYP enzyme
activity per kilogram often exceeds adult values during this developmental window, accelerating clearance of drugs
like phenobarbital, phenytoin, and levetiracetam. Plasma protein binding is actually reduced in infants (lower albumin
and alpha-1-acid glycoprotein), increasing free fraction. Extracellular fluid volume is increased, not decreased, diluting
the dose. APRNs must use weight-based pediatric dosing and monitor serum levels when available because infant
kinetics do not linearly scale from adult doses.
Q5: Which statement correctly characterizes a drug with a narrow therapeutic index (NTI) such as warfarin?
A. Toxic dose is dramatically higher than therapeutic dose, allowing wide dosing latitude
B. Small changes in dose or plasma concentration can produce serious toxicity or therapeutic failure
[CORRECT]
C. Monitoring plasma levels is unnecessary because efficacy reliably tracks dose
D. Genetic polymorphisms do not meaningfully affect dosing requirements
Correct Answer: B
Rationale: Narrow therapeutic index (NTI) drugs like warfarin, digoxin, lithium, phenytoin, and theophylline have
toxic concentrations very close to therapeutic concentrations, so modest dose or concentration changes can precipitate
harm or loss of efficacy. Therapeutic drug monitoring (TDM) is mandatory, and individualization is essential,
including pharmacogenomic considerations such as CYP2C9 and VKORC1 for warfarin. APRNs must counsel
patients on consistency (diet, adherence, interacting drugs) and monitor INR, serum levels, or other validated markers
rather than relying on dose alone.
Q6: A patient taking warfarin 5 mg daily for atrial fibrillation is newly started on amiodarone for rhythm
control. Within 3 weeks, the INR rises to 8.4 with no bleeding. Which pharmacokinetic mechanism best
explains this interaction?
A. Amiodarone induces CYP2C9, increasing warfarin activation
B. Amiodarone and its metabolite desethylamiodarone inhibit CYP2C9, reducing warfarin clearance
[CORRECT]
Page 2 | Verified Answers & Rationales
,NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
C. Amiodarone displaces warfarin from albumin only, with no clinical impact
D. Amiodarone enhances renal warfarin excretion
Correct Answer: B
Rationale: Amiodarone is a potent CYP2C9 inhibitor; both the parent drug and its active metabolite
desethylamiodarone reduce S-warfarin clearance, dramatically potentiating anticoagulation and requiring a 25-50%
empiric warfarin dose reduction. Although amiodarone also displaces warfarin from protein binding, this effect is
transient and clinically minor compared with the metabolic inhibition. CYP2C9 inhibition is the dominant mechanism.
APRNs should anticipate the interaction, check INR within 7-14 days, and adjust the warfarin dose proactively rather
than reactively.
Q7: A 72-year-old male with CKD stage 4 (eGFR 22 mL/min/1.73 m²) requires treatment for a confirmed
Pseudomonas urinary tract infection. The APRN selects gentamicin. Which pharmacokinetic principle guides
dosing?
A. Loading and maintenance doses both remain at standard adult values
B. Use standard loading dose but extend the dosing interval based on renal function [CORRECT]
C. Reduce loading dose and shorten the dosing interval
D. Switch to oral therapy because the patient has UTI only
Correct Answer: B
Rationale: For renally cleared drugs with a narrow therapeutic index such as aminoglycosides, the loading dose
(dependent on Vd) typically remains unchanged in renal impairment because Vd is not significantly altered, but the
maintenance interval must be extended (extended-interval dosing) or the maintenance dose reduced to prevent
accumulation. Oral gentamicin is not absorbed systemically and cannot treat systemic Pseudomonas. APRNs should
use a renal dosing calculator or the Cockcroft-Gault equation, monitor peak/trough levels (or area-under-curve targets),
and counsel patients on ototoxicity and nephrotoxicity warning signs.
Q8: Which drug exhibits the longest elimination half-life among the following, requiring weeks to reach
steady state?
A. Furosemide
B. Amiodarone [CORRECT]
C. Metformin
D. Lisinopril
Correct Answer: B
Rationale: Amiodarone has an exceptionally long half-life of approximately 25-60 days (and up to 100 days in some
individuals) due to extensive tissue distribution and slow lysosomal sequestration, meaning steady state may take 3-6
months to achieve. Furosemide (~2 hours), metformin (~6 hours), and lisinopril (~12 hours) all reach steady state
within 1-2 days. APRNs must load amiodarone inpatient or outpatient for 1-3 weeks (10 g total load) before
maintenance, and recognize that effects (and toxicity such as pulmonary fibrosis, hepatotoxicity, thyroid dysfunction)
persist for months after discontinuation.
Q9: A drug with high first-pass metabolism and low oral bioavailability is most likely administered by which
route for systemic effect?
A. Oral immediate-release tablet
B. Sublingual, transdermal, or intravenous [CORRECT]
C. Rectal suppository
Page 3 | Verified Answers & Rationales
, NR 566: Advanced Pharmacology for Care of the Family Final Exam | 2026-2027
D. Intramuscular depot only
Correct Answer: B
Rationale: Drugs undergoing extensive hepatic first-pass metabolism (e.g., nitroglycerin, propranolol, morphine,
verapamil, levodopa) have very low oral bioavailability (F). Alternative routes that bypass the portal
circulation-sublingual, transdermal, IV, or in some cases intranasal-are required for predictable systemic effect.
APRNs must recognize that switching routes changes more than convenience: the effective dose, onset, and duration
all change. For example, nitroglycerin sublingual (0.3-0.6 mg) is ~10x more bioavailable than oral, so doses are not
interchangeable.
Q10: A 45-year-old female with hypothyroidism is prescribed levothyroxine 100 mcg daily. She reports taking
it with her breakfast of high-fiber cereal and coffee with milk. Her TSH is 14 mIU/mL (target 0.5-4.0). What
pharmacokinetic mechanism explains her persistent hypothyroidism?
A. Levothyroxine undergoes extensive first-pass metabolism reducing bioavailability
B. Food, calcium in milk, and coffee reduce levothyroxine absorption [CORRECT]
C. Levothyroxine is metabolized faster when taken with food
D. TSH elevation indicates non-adherence rather than absorption issues
Correct Answer: B
Rationale: Levothyroxine absorption occurs in the proximal small intestine (jejunum) and is highly sensitive to
anything that chelates, binds, or accelerates transit. Calcium (milk, supplements), iron, fiber, soy, coffee, and proton
pump inhibitors all significantly reduce absorption. Levothyroxine has minimal first-pass metabolism; the issue is
absorption, not metabolism. APRNs must counsel patients to take levothyroxine on an empty stomach 30-60 minutes
before food or beverages other than water, or alternatively at bedtime 3-4 hours after the evening meal, and to space
interacting medications by at least 4 hours.
Q11: A drug that is a partial agonist at the beta-1 adrenergic receptor, such as carvedilol in a patient with
severe heart failure, demonstrates which pharmacodynamic property?
A. Maximal efficacy equal to a full agonist at all receptor occupancies
B. Acts as an antagonist in the presence of a full agonist and an agonist in the absence of endogenous
ligand [CORRECT]
C. Has zero intrinsic activity and only blocks the receptor
D. Cannot produce any therapeutic effect regardless of dose
Correct Answer: B
Rationale: Partial agonists (e.g., carvedilol, pindolol, buprenorphine, varenicline, beta blockers with intrinsic
sympathomimetic activity) have lower intrinsic activity than full agonists. In the presence of high endogenous agonist
(e.g., catecholamines in heart failure), they behave as antagonists by competing for the receptor while producing less
effect, reducing sympathetic overdrive. In the absence of endogenous agonist, they produce a modest agonist effect,
preventing complete receptor silence. APRNs must recognize this dual behavior to predict effects when combining
partial agonists with full agonists or antagonists.
Q12: A pregnant patient at 28 weeks' gestation requires phenytoin for new-onset epilepsy. Which
pharmacokinetic change of pregnancy most significantly affects phenytoin levels?
A. Increased plasma albumin raising total drug concentration
B. Increased volume of distribution, increased renal clearance, and reduced protein binding lowering
total drug levels [CORRECT]
C. Reduced hepatic CYP activity causing accumulation
Page 4 | Verified Answers & Rationales
